JP6419826B2 - 自閉症スペクトラム障害の治療のためのドーパミンd3受容体拮抗薬としてのクロモン誘導体 - Google Patents
自閉症スペクトラム障害の治療のためのドーパミンd3受容体拮抗薬としてのクロモン誘導体 Download PDFInfo
- Publication number
- JP6419826B2 JP6419826B2 JP2016538587A JP2016538587A JP6419826B2 JP 6419826 B2 JP6419826 B2 JP 6419826B2 JP 2016538587 A JP2016538587 A JP 2016538587A JP 2016538587 A JP2016538587 A JP 2016538587A JP 6419826 B2 JP6419826 B2 JP 6419826B2
- Authority
- JP
- Japan
- Prior art keywords
- dopamine
- treatment
- asd
- pharmaceutically acceptable
- dioxolo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/095—Oxytocins; Vasopressins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
A:数多くの状況にわたる社会的コミュニケーションおよび社会的相互作用(3項目全てが要求される)
・社会−感情的相互関係における欠陥
・社会的相互作用に用いられる非言語的な意思伝達の振る舞いにおける欠陥
・社会的関係性の構築および維持における欠陥
B:限られた繰り返される振る舞い(いずれか2項目が要求される)
・型にはまった、若しくは、繰り返される発言、身体の部位の動き、または物の使用
・日常的行動への過剰な執着、言語的または非言語的な振る舞いの儀式的様式、または変化への過剰な抵抗
・極めて(狭い範囲に)限定され執着された、その対象への集中強度が異常な興味関心
・感覚器を通しての入力に対する過反応性若しくは反応性低下、または周囲の状況についての感覚的様相への普通ではない興味関心
C:症状は発達初期に顕在化しなければならない。
D:症状は、臨床上顕著な社会的、職業的、または他の重要な最新の機能における障害を引き起こす。
E:これらの障害は、知的障害、または包括的な発育遅延では、よりよく説明できない。
・社会的行動の障害
・型にはまった、若しくは、繰り返される行動様式
・感覚およびコミュニケーションの障害
加えて、その表現型は、前頭前皮質における神経細胞の樹状突起の数または密度の減少等の、ASD特有の形態的再構成も含まれる(Bringas et al., Neuroscience 2013, vol 241, p 170-187)。これは、バルプロエートラットモデルに、ASDの病態生理学的動物モデルとしての構成概念妥当性および表面的妥当性を付与する。
N−(3−{4−[4−(8−オキソ−8H−[1,3]ジオキソロ[4,5−g]クロメン−7−イル)−ブチル]−ピペラジン−1−イル}−フェニル)−メタンスルフォンアミド塩酸塩は、ヒト組換えドーパミンD3受容体発現細胞またはヒト組換えドーパミンD2受容体発現細胞における、本発明に従ったそのレセプターに対するドーパミンD3受容体リガンドおよびモジュレーターとしてのインビトロの活性により評価された。阻害定数(Ki)は、キューサックらの文献(Cussac et al., in Naunyn-Schmiedeberg's Arch. Pharmacol. 2000, vol 361, p 569-572)に記載された、[3H]スピペロンの結合の阻害により測定された。発明者らは、本発明化合物が、Ki値が0.17〜ナノモル/Lである、強力なドーパミンD3受容体リガンドとして作用することを示した。この化合物は、ドーパミンD2受容体リガンドに対しては、検出可能な親和性(71倍弱い)を示した。
N−(3−{4−[4−(8−オキソ−8H−[1,3]ジオキソロ[4,5−g]クロメン−7−イル)−ブチル]−ピペラジン−1−イル}−フェニル)−メタンスルフォンアミド塩酸塩は、バルプロ酸ナトリウム塩を投与された雌ラットからの出生児の社会的相互作用に関して試験された。自閉症についてのバルプロ酸ラットモデルの実験の設定は、発表されているデータ(Dendrinos et al., Front. Integr. Neurosci. 2011, vol 5, art 68; Markram et al., Neuropsychopharm. 2007, vol 33, p 901-912; Schneider et al., Neuropsychopharm. 2005, vol 30, p 80-89)に適合させた。
妊娠している(最大胎生期8日)雌スプラーグドーリーラット(OFA (SD) Charles River Lyon, France)は、4日間隔離された。動物は、環境的に調節された部屋(温度21±1℃、相対湿度55±5%)中、12時間おきの明暗サイクル(午前7時にライトは点灯する)の下で、食餌(A04, Safe, Augy, France)および濾過水(孔直径は0.2μm)を自由に摂取できる、フルボトムケージ(ML-H Cage, 370x235x180 mm, LxWxH; floor surface 870 cm2)に、ケージ毎に2匹ずつ収容された。出生児を離乳させるまでは、動物は、できる限り邪魔しないように、1週間に1回だけしか変えなかった。環境的富化(営巣材料)を提供した。
生理食塩水またはバルプロエートナトリウムのいずれかで処理された母親からの出生児の社会的相互作用の振る舞いに関する本発明化合物の急性投与の効果は、図1に概略が示される。示されたデータは、平均値±平均値に対する標準誤差、n=10匹のラット(5匹の雄ラットおよび5匹の雌ラット)である。本発明化合物は、生理食塩水で処理された母親からの出生児における社会的相互作用の振る舞いには顕著な効果をもたらさなかった。本発明化合物を0.63mg/kg投与した場合に、出生前のバルプロエートナトリウムへの曝露により引き起こされた社会的相互作用の欠陥を顕著に軽減した。本発明化合物を2.5mg/kg投与した場合に、これらの欠陥は完全に逆転させられた。本発明化合物は、自閉症スペクトラム障害および特に社会的相互作用の欠陥の治療のための興味深い製品であると考えられる。
Claims (7)
- 自閉症スペクトラム障害の治療を目的とする薬剤の製造のための、N−(3−{4−[4−(8−オキソ−8H−[1,3]ジオキソロ[4,5−g]クロメン−7−イル)−ブチル]−ピペラジン−1−イル}−フェニル)−メタンスルフォンアミドまたはその薬学的に許容可能な塩の使用。
- N−(3−{4−[4−(8−オキソ−8H−[1,3]ジオキソロ[4,5−g]クロメン−7−イル)−ブチル]−ピペラジン−1−イル}−フェニル)−メタンスルフォンアミドの薬学的に許容可能な塩が塩酸塩である、請求項1に記載の使用。
- 前記薬剤が社会的相互作用の欠陥の治療を目的とするものである、請求項1または2に記載の使用。
- N−(3−{4−[4−(8−オキソ−8H−[1,3]ジオキソロ[4,5−g]クロメン−7−イル)−ブチル]−ピペラジン−1−イル}−フェニル)−メタンスルフォンアミドまたはその薬学的に許容可能な塩と薬学的に許容可能な賦形剤とを含んでなる、自閉症スペクトラム障害の治療のための医薬組成物。
- N−(3−{4−[4−(8−オキソ−8H−[1,3]ジオキソロ[4,5−g]クロメン−7−イル)−ブチル]−ピペラジン−1−イル}−フェニル)−メタンスルフォンアミドの薬学的に許容可能な塩が塩酸塩である、請求項4に記載の使用のための医薬組成物。
- 社会的相互作用の欠陥の治療のための、請求項4または5に記載の使用のための医薬組成物。
- メマンチン、アマンタジン、バクロフェン、R−バクロフェン、フェノバム(phenobam)、アカンプロセート、ブメタミド(bumetamide)、カルピプラミン、オキシトシン、バソプレシンおよびこれらの混合物、からなる群から選択される化合物と組合せられた、請求項4〜6のいずれか一項に記載の使用のための医薬組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13306726 | 2013-12-13 | ||
EP13306726.4 | 2013-12-13 | ||
PCT/EP2014/077635 WO2015086836A1 (en) | 2013-12-13 | 2014-12-12 | A chromone derivative as a dopamine d3 receptor antagonist for its use for the treatment of autism spectrum disorder |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2016540000A JP2016540000A (ja) | 2016-12-22 |
JP2016540000A5 JP2016540000A5 (ja) | 2018-02-01 |
JP6419826B2 true JP6419826B2 (ja) | 2018-11-07 |
Family
ID=49883003
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016538587A Expired - Fee Related JP6419826B2 (ja) | 2013-12-13 | 2014-12-12 | 自閉症スペクトラム障害の治療のためのドーパミンd3受容体拮抗薬としてのクロモン誘導体 |
Country Status (30)
Country | Link |
---|---|
US (1) | US10028948B2 (ja) |
EP (1) | EP3079688B1 (ja) |
JP (1) | JP6419826B2 (ja) |
KR (1) | KR102280530B1 (ja) |
CN (1) | CN105792824B (ja) |
AU (1) | AU2014363428B2 (ja) |
BR (1) | BR112016012552A8 (ja) |
CA (1) | CA2932791C (ja) |
CY (1) | CY1119907T1 (ja) |
DK (1) | DK3079688T3 (ja) |
ES (1) | ES2657706T3 (ja) |
HK (1) | HK1223563A1 (ja) |
HR (1) | HRP20180323T8 (ja) |
HU (1) | HUE036035T2 (ja) |
IL (1) | IL245996B (ja) |
LT (1) | LT3079688T (ja) |
MA (1) | MA39076A1 (ja) |
MX (1) | MX2016007612A (ja) |
MY (1) | MY172937A (ja) |
NO (1) | NO3079688T3 (ja) |
NZ (1) | NZ720868A (ja) |
PL (1) | PL3079688T3 (ja) |
PT (1) | PT3079688T (ja) |
RS (1) | RS56931B1 (ja) |
RU (2) | RU2686110C1 (ja) |
SA (1) | SA516371298B1 (ja) |
SI (1) | SI3079688T1 (ja) |
TN (1) | TN2016000213A1 (ja) |
UA (1) | UA117271C2 (ja) |
WO (1) | WO2015086836A1 (ja) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AP2975A (en) | 2008-07-16 | 2014-09-30 | Richter Gedeon Nyrt | Pharmaceutical formulations containing dopamine receptor ligands |
US11274087B2 (en) | 2016-07-08 | 2022-03-15 | Richter Gedeon Nyrt. | Industrial process for the preparation of cariprazine |
US11547707B2 (en) | 2019-04-10 | 2023-01-10 | Richter Gedeon Nyrt. | Carbamoyl cyclohexane derivatives for treating autism spectrum disorder |
HU231500B1 (hu) | 2019-04-10 | 2024-04-28 | Richter Gedeon Nyrt | Karbamoil-ciklohexán származékok autizmus spektrum betegség kezelésére |
KR20220021157A (ko) | 2020-08-13 | 2022-02-22 | 원광대학교산학협력단 | 옥시토신 호르몬 증가효과를 갖는 자폐스펙트럼장애 아동 개선용 교육시스템 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2682953B1 (fr) * | 1991-10-23 | 1995-04-21 | Inst Nat Sante Rech Med | Nouveaux derives de naphtamides, leur procede de preparation et leur application dans le domaine therapeutique. |
DE4229880A1 (de) * | 1992-09-04 | 1994-03-31 | Knauf Siegfried | Medikament bzw. Medikamentenzusammensetzung |
SK4782001A3 (en) * | 1998-10-08 | 2001-11-06 | Smithkline Beecham Plc | Tetrahydrobenzazepine derivatives useful as modulators of dopamine d3 receptors (antipsychotic agents) |
WO2006034187A2 (en) * | 2004-09-20 | 2006-03-30 | Mount Sinai School Of Medicine | Use of memantine (namenda) to treat autism, compulsivity, and impulsivity |
EP2263665A1 (en) | 2009-06-02 | 2010-12-22 | Pharnext | New compositions for treating CMT and related disorders |
FR2949465B1 (fr) * | 2009-09-01 | 2011-08-12 | Pf Medicament | Derives chromones, leur procede de preparation et leurs applications therapeutiques |
US20110294879A1 (en) * | 2010-05-28 | 2011-12-01 | Xenoport, Inc. | Method of treatment of fragile x syndrome, down's syndrome, autism and related disorders |
KR101921772B1 (ko) * | 2011-05-13 | 2018-11-23 | 가부시키가이샤 한도오따이 에네루기 켄큐쇼 | 반도체 장치 |
FR2976179A1 (fr) * | 2011-06-09 | 2012-12-14 | Pf Medicament | Utilisation de la carpipramine dans le traitement de troubles psychiatriques et du developpement chez l'enfant et l'adolescent |
-
2014
- 2014-12-12 RU RU2016125829A patent/RU2686110C1/ru active
- 2014-12-12 RS RS20180196A patent/RS56931B1/sr unknown
- 2014-12-12 HU HUE14812465A patent/HUE036035T2/hu unknown
- 2014-12-12 US US15/103,470 patent/US10028948B2/en active Active
- 2014-12-12 ES ES14812465.4T patent/ES2657706T3/es active Active
- 2014-12-12 WO PCT/EP2014/077635 patent/WO2015086836A1/en active Application Filing
- 2014-12-12 MY MYPI2016702136A patent/MY172937A/en unknown
- 2014-12-12 CA CA2932791A patent/CA2932791C/en active Active
- 2014-12-12 TN TN2016000213A patent/TN2016000213A1/en unknown
- 2014-12-12 DK DK14812465.4T patent/DK3079688T3/da active
- 2014-12-12 NZ NZ720868A patent/NZ720868A/en not_active IP Right Cessation
- 2014-12-12 RU RU2019104946A patent/RU2019104946A/ru unknown
- 2014-12-12 PL PL14812465T patent/PL3079688T3/pl unknown
- 2014-12-12 CN CN201480066587.4A patent/CN105792824B/zh not_active Expired - Fee Related
- 2014-12-12 SI SI201430603T patent/SI3079688T1/en unknown
- 2014-12-12 PT PT148124654T patent/PT3079688T/pt unknown
- 2014-12-12 EP EP14812465.4A patent/EP3079688B1/en active Active
- 2014-12-12 KR KR1020167015313A patent/KR102280530B1/ko active IP Right Grant
- 2014-12-12 BR BR112016012552A patent/BR112016012552A8/pt not_active Application Discontinuation
- 2014-12-12 MX MX2016007612A patent/MX2016007612A/es active IP Right Grant
- 2014-12-12 MA MA39076A patent/MA39076A1/fr unknown
- 2014-12-12 NO NO14812465A patent/NO3079688T3/no unknown
- 2014-12-12 UA UAA201607311A patent/UA117271C2/uk unknown
- 2014-12-12 LT LTEP14812465.4T patent/LT3079688T/lt unknown
- 2014-12-12 AU AU2014363428A patent/AU2014363428B2/en not_active Ceased
- 2014-12-12 JP JP2016538587A patent/JP6419826B2/ja not_active Expired - Fee Related
-
2016
- 2016-06-02 IL IL245996A patent/IL245996B/en active IP Right Grant
- 2016-06-12 SA SA516371298A patent/SA516371298B1/ar unknown
- 2016-10-17 HK HK16111955.2A patent/HK1223563A1/zh not_active IP Right Cessation
-
2018
- 2018-02-09 CY CY20181100159T patent/CY1119907T1/el unknown
- 2018-02-22 HR HRP20180323TT patent/HRP20180323T8/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6419826B2 (ja) | 自閉症スペクトラム障害の治療のためのドーパミンd3受容体拮抗薬としてのクロモン誘導体 | |
Banerjee et al. | Does serotonin deficit mediate susceptibility to ADHD? | |
Erk et al. | Hippocampal and frontolimbic function as intermediate phenotype for psychosis: evidence from healthy relatives and a common risk variant in CACNA1C | |
Winder-Rhodes et al. | Effects of modafinil and prazosin on cognitive and physiological functions in healthy volunteers | |
Santana-Coelho et al. | Advancing autism research from mice to marmosets: Behavioral development of offspring following prenatal maternal immune activation | |
KR102549061B1 (ko) | App 의 정상 가공을 촉진하는 화합물 | |
Haram et al. | An attempt to identify single nucleotide polymorphisms contributing to possible relationships between personality traits and oxytocin-related genes | |
WO2022047212A1 (en) | Compositions and methods for treating neurodegenerative disorders | |
OA17906A (en) | A chromone derivative as a dopamine D3 receptor antagonist for its use for the treatment of autism spectrum disorder. | |
WO2020165802A1 (en) | Compositions and methods relating to use of agonists of alpha5-containing gabaa receptors | |
Greenblatt et al. | Accidental poisoning with psychotropic drugs in children | |
TW201035081A (en) | Novel pharmaceutical composition for treatment of schizophrenia | |
US20220096515A1 (en) | Methods and Formulations for Preventing Neurological or Psychiatric Disorders | |
Prananjaya et al. | DRD2 Gene Polymorphisms in Schizophrenia Patients | |
WO2022087456A1 (en) | New compounds for the treatment of alzheimer's disease | |
Shaw | Identifying phenotypic change across time in mouse models of Down syndrome | |
JP2024512569A (ja) | 治療におけるadnfポリペプチドの使用 | |
US20180289655A1 (en) | Methods and Compositions for the Intravenous Administration of Fumarates for the Treatment of Neurological Diseases | |
Grieco | Minocycline Treatment and the Necessity to Develop a Novel Outcome Measure for Children with Angelman Syndrome | |
Jensen | Serotonin: from mouse models to human disorders | |
Centers | A Rise in Fentanyl-Laced Heroin Deaths |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20171212 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20171212 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20180831 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20180911 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20181010 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6419826 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |